Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clearmind Medicine Inc
(CSE:
CMND
)
N/A
UNCHANGED
Last Price
Updated: 3:54 PM EDT, Mar 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc
< Previous
1
2
3
4
Next >
Clearmind Medicine Announces Shareholders Meeting Results
November 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Closes US$2.25 Million Public Offering
September 18, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
September 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
September 06, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
August 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
July 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
June 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
May 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
May 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
May 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
May 12, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
May 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
May 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
April 27, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
April 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
April 20, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Closes US$3.5 Million Public Offering
April 06, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
April 04, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
March 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
March 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
Clearmind Medicine submitted patent applications to protect the novel compounds
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.